Microtubule stabilizing agents: Their molecular signaling consequences and the potential for enhancement by drug combination

Schiff, 1979, Promotion of microtubule assembly in vitro by Taxol, Nature, 277, 665, 10.1038/277665a0 Schiff, 1980, Taxol stabilizes microtubules in mouse fibroblast cells, Proc Natl Acad Sci USA, 77, 1561, 10.1073/pnas.77.3.1561 Ojima, 1999, A common pharmacophore for cytotoxic natural products that stabilize microtubules, Proc Natl Acad Sci USA, 96, 4256, 10.1073/pnas.96.8.4256 Rao, 1999, Characterization of the Taxol binding site on the microtubule. Identification of Arg(282) in β-tubulin as the site of photoincorporation of a 7-benzophenone analogue of Taxol, J Biol Chem, 274, 37990, 10.1074/jbc.274.53.37990 Jordan, 1996, Mitotic block induced in HeLa cells by low concentrations of paclitaxel (Taxol) results in abnormal mitotic exit and apoptotic cell death, Cancer Res, 56, 816 Yvon, 1999, Taxol suppresses dynamics of individual microtubules in living human tumor cells, Mol Biol Cell, 10, 947, 10.1091/mbc.10.4.947 Blagosklonny, 1999, Molecular effects of paclitaxel: myths and reality (a critical review), Int J Cancer, 83, 151, 10.1002/(SICI)1097-0215(19991008)83:2<151::AID-IJC1>3.0.CO;2-5 Rowinsky, 2002, Taxane analogues: distinguishing royal robes from the “Emperor’s New Clothes, Clin Cancer Res, 8, 2759 Rowinsky, 1997, The development and clinical utility of the taxane class of antimicrotubule chemotherapy agents, Annu Rev Med, 48, 353, 10.1146/annurev.med.48.1.353 Wani, 1971, Plant antitumor agents. VI. Isolation and structure of Taxol, a novel antileukemic and antitumor agent from Taxus brevifolia, J Am Chem Soc, 93, 2325, 10.1021/ja00738a045 Chan, 2000, The immunological effects of taxanes, Cancer Immunol Immunother, 49, 181, 10.1007/s002620000122 Gerth, 1996, Epothilons A and B: antifungal and cytotoxic compounds from Sorangium cellulosum (Myxobacteria). Production, physico-chemical and biological properties, J Antibiot (Tokyo), 49, 560, 10.7164/antibiotics.49.560 Bollag, 1995, Epothilones, a new class of microtubule stabilizing agents with a Taxol-like mechanism of action, Cancer Res, 55, 2325 Bergstralh, 2004, A comparison of signaling activities induced by Taxol and desoxyepothilone B, J Chemother, 16, 563, 10.1179/joc.2004.16.6.563 Mani, 2004, The clinical development of new mitotic inhibitors that stabilize the microtubule, Anticancer Drugs, 15, 553, 10.1097/01.cad.0000131681.21637.b2 Goodin, 2004, Epothilones: mechanism of action and biologic activity, J Clin Oncol, 22, 2015, 10.1200/JCO.2004.12.001 Mooberry, 1999, Laulimalide and isolaulimalide, new paclitaxel-like microtubule stabilizing agents, Cancer Res, 59, 653 Lindel, 1997, Eleutherobin, a new cytotoxin that mimics paclitaxel (Taxol) by stabilizing microtubules, J Am Chem Soc, 119, 8744, 10.1021/ja9717828 Long, 1998, Eleutherobin, a novel cytotoxic agent that induces tubulin polymerization, is similar to paclitaxel (Taxol), Cancer Res, 58, 1111 Longley, 1991, Discodermolide – a new, marine-derived immunosuppressive compound. I. In vitro studies, Transplantation, 52, 650, 10.1097/00007890-199110000-00014 Longley, 1991, Discodermolide – a new, marine-derived immunosuppressive compound. II. In vivo studies, Transplantation, 52, 656, 10.1097/00007890-199110000-00015 Gunasekera, 2002, Five new discodermolide analogues from the marine sponge Discodermia species, J Nat Prod, 65, 1643, 10.1021/np020219m ter Haar, 1996, Discodermolide, a cytotoxic marine agent that stabilizes microtubules more potently than Taxol, Biochemistry, 35, 243, 10.1021/bi9515127 Kowalski, 1997, The microtubule stabilizing agent discodermolide competitively inhibits the binding of paclitaxel (Taxol) to tubulin polymers, enhances tubulin nucleation reactions more potently than paclitaxel, and inhibits the growth of paclitaxel-resistant cells, Mol Pharmacol, 52, 613, 10.1124/mol.52.4.613 Martello, 2001, The relationship between Taxol and (+)-discodermolide: synthetic analogs and modeling studies, Chem Biol, 8, 843, 10.1016/S1074-5521(01)00055-2 Martello, 2000, Taxol and discodermolide represent a synergistic drug combination in human carcinoma cell lines, Clin Cancer Res, 6, 1978 Klein, 2005, The microtubule stabilizing agent discodermolide is a potent inducer of accelerated cell senescence, Cell Cycle, 4, 501, 10.4161/cc.4.3.1550 Mita, 2004, A phase I pharmacokinetic (PK) trial of XAA296A (Discodermolide) administered every 3 weeks to adult patients with advanced solid malignancies (ABSTRACT), J Clin Oncol, 22, 2025, 10.1200/jco.2004.22.14_suppl.2025 Makin, 2001, Modulating sensitivity to drug-induced apoptosis: the future for chemotherapy?, Breast Cancer Res, 3, 150, 10.1186/bcr289 Rigas, 2004, Taxane-platinum combinations in advanced non-small cell lung cancer: a review, Oncologist, 9, 16, 10.1634/theoncologist.9-suppl_2-16 Kosmidis, 2002, Paclitaxel plus carboplatin versus gemcitabine plus paclitaxel in advanced non-small-cell lung cancer: a phase III randomized trial, J Clin Oncol, 20, 3578, 10.1200/JCO.2002.12.112 Athanasiadis, 2005, Paclitaxel and gemcitabine combination in a biweekly schedule in patients with advanced non small-cell lung cancer: a phase I study, Cancer Chemother Pharmacol, 56, 653, 10.1007/s00280-005-1009-0 Nabholtz, 2003, Docetaxel–anthracycline combinations in metastatic breast cancer, Breast Cancer Res Treat, 79, S3, 10.1023/A:1024369220605 Ho, 2003, Platinum-based anticancer agents: innovative design strategies and biological perspectives, Med Res Rev, 23, 633, 10.1002/med.10038 Manegold, 2000, Gemcitabine in non-small cell lung cancer NSCLC, Invest New Drugs, 18, 29, 10.1023/A:1006327729228 Sandler, 1999, Gemcitabine: single-agent and combination therapy in non-small cell lung cancer, Oncologist, 4, 241, 10.1634/theoncologist.4-3-241 Gewirtz, 1999, A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin, Biochem Pharmacol, 57, 727, 10.1016/S0006-2952(98)00307-4 Greulich, 1998, An analysis of Mek1 signaling in cell proliferation and transformation, J Biol Chem, 273, 13280, 10.1074/jbc.273.21.13280 Tibbles, 1999, The stress-activated protein kinase pathways, Cell Mol Life Sci, 55, 1230, 10.1007/s000180050369 Lee, 1998, Paclitaxel (Taxol)-induced gene expression and cell death are both mediated by the activation of c-Jun NH2-terminal kinase (JNK/SAPK), J Biol Chem, 273, 28253, 10.1074/jbc.273.43.28253 Seidman, 2001, The role of ERK 1/2 and p38 MAP-kinase pathways in Taxol-induced apoptosis in human ovarian carcinoma cells, Exp Cell Res, 268, 84, 10.1006/excr.2001.5262 Sebolt-Leopold, 2000, Development of anticancer drugs targeting the MAP kinase pathway, Oncogene, 19, 6594, 10.1038/sj.onc.1204083 Sebolt-Leopold, 2004, Targeting the mitogen-activated protein kinase cascade to treat cancer, Nat Rev Cancer, 4, 937, 10.1038/nrc1503 MacKeigan, 2000, MEK inhibition enhances paclitaxel-induced tumor apoptosis, J Biol Chem, 275, 38953, 10.1074/jbc.C000684200 McDaid, 2001, Selective potentiation of paclitaxel (Taxol)-induced cell death by mitogen-activated protein kinase inhibition in human cancer cell lines, Mol Pharmacol, 60, 290, 10.1124/mol.60.2.290 Yu, 2001, Sequence-dependent potentiation of paclitaxel-mediated apoptosis in human leukemia cells by inhibitors of the mitogen-activated protein kinase/mitogen-activated protein kinase pathway, Mol Pharmacol, 60, 143, 10.1124/mol.60.1.143 Yacoub, 2003, Sequence dependent exposure of mammary carcinoma cells to Taxotere and the MEK1/2 inhibitor U0126 causes enhanced cell killing in vitro, Cancer Biol Ther, 2, 670, 10.4161/cbt.2.6.534 Allen, 2003, CI-1040 (PD184352), a targeted signal transduction inhibitor of MEK (MAPKK), Semin Oncol, 30, 105, 10.1053/j.seminoncol.2003.08.012 Sebolt-Leopold, 1999, Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo, Nat Med, 5, 810, 10.1038/10533 McDaid, 2005, Enhancement of the therapeutic efficacy of Taxol by the mitogen-activated protein kinase inhibitor CI-1040 in nude mice bearing human heterotransplants, Cancer Res, 65, 2854, 10.1158/0008-5472.CAN-04-4391 Lorusso, 2005, Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies, J Clin Oncol, 23, 5281, 10.1200/JCO.2005.14.415 Rinehart, 2004, Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer, J Clin Oncol, 22, 4456, 10.1200/JCO.2004.01.185 Taxman, 2003, Transcriptional profiling of targets for combination therapy of lung carcinoma with paclitaxel and mitogen-activated protein/extracellular signal-regulated kinase inhibitor, Cancer Res, 63, 5095 MacKeigan, 2003, Proteomic profiling drug-induced apoptosis in non-small cell lung carcinoma: identification of RS/DJ-1 and RhoGDIα, Cancer Res, 63, 6928 Yang, 2000, Taxol mediates serine phosphorylation of the 66kDa Shc isoform, Cancer Res, 60, 5171 Brantley-Finley, 2003, The JNK, ERK and p53 pathways play distinct roles in apoptosis mediated by the antitumor agents vinblastine, doxorubicin, and etoposide, Biochem Pharmacol, 66, 459, 10.1016/S0006-2952(03)00255-7 Chung, 2003, Phosphorylation of Cdc20 is required for its inhibition by the spindle checkpoint, Nat Cell Biol, 5, 748, 10.1038/ncb1022 Kops, 2005, On the road to cancer: aneuploidy and the mitotic checkpoint, Nat Rev Cancer, 5, 773, 10.1038/nrc1714 Bharadwaj, 2004, The spindle checkpoint, aneuploidy, and cancer, Oncogene, 23, 2016, 10.1038/sj.onc.1207374 Sorger, 1997, Coupling cell division and cell death to microtubule dynamics, Curr Opin Cell Biol, 9, 807, 10.1016/S0955-0674(97)80081-6 Waters, 1998, Localization of Mad2 to kinetochores depends on microtubule attachment, not tension, J Cell Biol, 141, 1181, 10.1083/jcb.141.5.1181 Martinez-Exposito, 1999, Retention of the BUB3 checkpoint protein on lagging chromosomes, Proc Natl Acad Sci USA, 96, 8493, 10.1073/pnas.96.15.8493 Huang, 2000, Activation of MAD 2 checkprotein and persistence of cyclin B1/CDC 2 activity associate with paclitaxel-induced apoptosis in human nasopharyngeal carcinoma cells, Apoptosis, 5, 235, 10.1023/A:1009652412399 Blajeski, 2001, A multistep model for paclitaxel-induced apoptosis in human breast cancer cell lines, Exp Cell Res, 270, 277, 10.1006/excr.2001.5349 Chen, 2003, Gene expression and mitotic exit induced by microtubule stabilizing drugs, Cancer Res, 63, 7891 Tao, 2005, Induction of apoptosis by an inhibitor of the mitotic kinesin KSP requires both activation of the spindle assembly checkpoint and mitotic slippage, Cancer Cell, 8, 49, 10.1016/j.ccr.2005.06.003 Anand, 2003, AURORA-A amplification overrides the mitotic spindle assembly checkpoint, inducing resistance to Taxol, Cancer Cell, 3, 51, 10.1016/S1535-6108(02)00235-0 Pages, 1993, Mitogen-activated protein kinases p42mapk and p44mapk are required for fibroblast proliferation, Proc Natl Acad Sci USA, 90, 8319, 10.1073/pnas.90.18.8319 Cowley, 1994, Activation of MAP kinase is necessary and sufficient for PC12 differentiation and for transformation of NIH 3T3 cells, Cell, 77, 841, 10.1016/0092-8674(94)90133-3 Mansour, 1994, Transformation of mammalian cells by constitutively active MAP kinase, Science, 265, 966, 10.1126/science.8052857 Roovers, 2000, Integrating the MAP kinase signal into the G1 phase cell cycle machinery, Bioessays, 22, 818, 10.1002/1521-1878(200009)22:9<818::AID-BIES7>3.0.CO;2-6 Maller, 2002, The mechanism of CSF arrest in vertebrate oocytes, Mol Cell Endocrinol, 187, 173, 10.1016/S0303-7207(01)00695-5 Posada, 1993, Mos stimulates MAP kinase in Xenopus oocytes and activates a MAP kinase in vitro, Mol Cell Biol, 13, 2546, 10.1128/MCB.13.4.2546 Shapiro, 1998, Activation of the MKK/ERK pathway during somatic cell mitosis: direct interactions of active ERK with kinetochores and regulation of the mitotic 3F3/2 phosphoantigen, J Cell Biol, 142, 1533, 10.1083/jcb.142.6.1533 Guadagno, 1998, Requirement for MAPK activation for normal mitotic progression in Xenopus egg extracts, Science, 282, 1312, 10.1126/science.282.5392.1312 Liu, 2004, The MAP kinase pathway is required for entry into mitosis and cell survival, Oncogene, 23, 763, 10.1038/sj.onc.1207188 Seger, 1995, The MAPK signaling cascade, Faseb J, 9, 726, 10.1096/fasebj.9.9.7601337 Crews, 1992, The primary structure of MEK, a protein kinase that phosphorylates the ERK gene product, Science, 258, 478, 10.1126/science.1411546 Seger, 1992, Human T-cell mitogen-activated protein kinases are related to yeast signal transduction kinases, J Biol Chem, 267, 25628, 10.1016/S0021-9258(18)35648-5 Fang, 1998, “Loop” domain is necessary for Taxol-induced mobility shift and phosphorylation of Bcl-2 as well as for inhibiting Taxol-induced cytosolic accumulation of cytochrome c and apoptosis, Cancer Res, 58, 3202 Srivastava, 1999, Deletion of the loop region of Bcl-2 completely blocks paclitaxel-induced apoptosis, Proc Natl Acad Sci USA, 96, 3775, 10.1073/pnas.96.7.3775 Wang, 1994, Apoptosis regulation by interaction of Bcl-2 protein and Raf-1 kinase, Oncogene, 9, 2751 Blagosklonny, 1997, Raf-1/bcl-2 phosphorylation: a step from microtubule damage to cell death, Cancer Res, 57, 130 Lee, 2003, Down-regulation of Raf-1 kinase is associated with paclitaxel resistance in human breast cancer MCF-7/Adr cells, Cancer Lett, 193, 57, 10.1016/S0304-3835(02)00722-X Cheung, 2004, Id-1-induced Raf/MEK pathway activation is essential for its protective role against Taxol-induced apoptosis in nasopharyngeal carcinoma cells, Carcinogenesis, 25, 881, 10.1093/carcin/bgh087 Yue, 2004, Mos mediates the mitotic activation of p42 MAPK in Xenopus egg extracts, Curr Biol, 14, 1581, 10.1016/j.cub.2004.08.056 Ling, 1998, Paclitaxel-induced apoptosis is associated with expression and activation of c-Mos gene product in human ovarian carcinoma SKOV3 cells, Cancer Res, 58, 3633 Blagosklonny, 1999, Mitogen-activated protein kinase pathway is dispensable for microtubule-active drug-induced Raf-1/Bcl-2 phosphorylation and apoptosis in leukemia cells, Leukemia, 13, 1028, 10.1038/sj.leu.2401449 Minshull, 1994, A MAP kinase-dependent spindle assembly checkpoint in Xenopus egg extracts, Cell, 79, 475, 10.1016/0092-8674(94)90256-9 Takenaka, 1997, MAP kinase is required for the spindle assembly checkpoint but is dispensable for the normal M phase entry and exit in Xenopus egg cell cycle extracts, J Cell Biol, 136, 1091, 10.1083/jcb.136.5.1091 Wang, 1997, A role for mitogen-activated protein kinase in the spindle assembly checkpoint in XTC cells, J Cell Biol, 137, 433, 10.1083/jcb.137.2.433 Gachet, 2001, A MAP kinase-dependent actin checkpoint ensures proper spindle orientation in fission yeast, Nature, 412, 352, 10.1038/35085604 Johnson, 2004, Bub1 is required for kinetochore localization of BubR1, Cenp-E, Cenp-F and Mad2, and chromosome congression, J Cell Sci, 117, 1577, 10.1242/jcs.01006 Wang, 1994, Mos oncogene product associates with kinetochores in mammalian somatic cells and disrupts mitotic progression, Proc Natl Acad Sci USA, 91, 8329, 10.1073/pnas.91.18.8329 Taylor, 1997, Kinetochore localization of murine Bub1 is required for normal mitotic timing and checkpoint response to spindle damage, Cell, 89, 727, 10.1016/S0092-8674(00)80255-X Reszka, 1995, Association of mitogen-activated protein kinase with the microtubule cytoskeleton, Proc Natl Acad Sci USA, 92, 8881, 10.1073/pnas.92.19.8881 Schwab, 2001, Bub1 is activated by the protein kinase p90(Rsk) during Xenopus oocyte maturation, Curr Biol, 11, 141, 10.1016/S0960-9822(01)00045-8 Tunquist, 2002, The spindle checkpoint kinase bub1 and cyclin e/cdk2 both contribute to the establishment of meiotic metaphase arrest by cytostatic factor, Curr Biol, 12, 1027, 10.1016/S0960-9822(02)00894-1 Ohi, 1999, Regulating the onset of mitosis, Curr Opin Cell Biol, 11, 267, 10.1016/S0955-0674(99)80036-2 Tan, 2005, Essential tension and constructive destruction: the spindle checkpoint and its regulatory links with mitotic exit, Biochem J, 386, 1, 10.1042/BJ20041415 Ling, 1998, Accumulation of cyclin B1, activation of cyclin B1-dependent kinase and induction of programmed cell death in human epidermoid carcinoma KB cells treated with Taxol, Int J Cancer, 75, 925, 10.1002/(SICI)1097-0215(19980316)75:6<925::AID-IJC16>3.0.CO;2-1 Bible, 1997, Cytotoxic synergy between flavopiridol (NSC 649890, L86-8275) and various antineoplastic agents: the importance of sequence of administration, Cancer Res, 57, 3375 Yu, 1998, Overexpression of ErbB2 blocks Taxol-induced apoptosis by upregulation of p21Cip1, which inhibits p34Cdc2 kinase, Mol Cell, 2, 581, 10.1016/S1097-2765(00)80157-4 Motwani, 1999, Sequential dependent enhancement of caspase activation and apoptosis by flavopiridol on paclitaxel-treated human gastric and breast cancer cells, Clin Cancer Res, 5, 1876 O’Connor, 2002, A p34(cdc2) survival checkpoint in cancer, Cancer Cell, 2, 43, 10.1016/S1535-6108(02)00084-3 Pennati, 2005, Potentiation of paclitaxel-induced apoptosis by the novel cyclin-dependent kinase inhibitor NU6140: a possible role for survivin down-regulation, Mol Cancer Ther, 4, 1328, 10.1158/1535-7163.MCT-05-0022 Shapiro, 2004, Preclinical and clinical development of the cyclin-dependent kinase inhibitor flavopiridol, Clin Cancer Res, 10, 4270s, 10.1158/1078-0432.CCR-040020 Senderowicz, 2003, Small-molecule cyclin-dependent kinase modulators, Oncogene, 22, 6609, 10.1038/sj.onc.1206954 Abrieu, 2001, The interplay between cyclin-B-Cdc2 kinase (MPF) and MAP kinase during maturation of oocytes, J Cell Sci, 114, 257, 10.1242/jcs.114.2.257 O’Connor, 2000, Regulation of apoptosis at cell division by p34cdc2 phosphorylation of survivin, Proc Natl Acad Sci USA, 97, 13103, 10.1073/pnas.240390697 Ambrosini, 1997, A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma, Nat Med, 3, 917, 10.1038/nm0897-917 Li, 1998, Control of apoptosis and mitotic spindle checkpoint by survivin, Nature, 396, 580, 10.1038/25141 Fortugno, 2002, Survivin exists in immunochemically distinct subcellular pools and is involved in spindle microtubule function, J Cell Sci, 115, 575, 10.1242/jcs.115.3.575 Skoufias, 2000, Human survivin is a kinetochore-associated passenger protein, J Cell Biol, 151, 1575, 10.1083/jcb.151.7.1575 Adams, 2001, Chromosomal passengers and the (aurora) ABCs of mitosis, Trends Cell Biol, 11, 49, 10.1016/S0962-8924(00)01880-8 Lens, 2003, Survivin is required for a sustained spindle checkpoint arrest in response to lack of tension, Embo J, 22, 2934, 10.1093/emboj/cdg307 Ditchfield, 2003, Aurora B couples chromosome alignment with anaphase by targeting BubR1, Mad2, and Cenp-E to kinetochores, J Cell Biol, 161, 267, 10.1083/jcb.200208091 Hauf, 2003, The small molecule Hesperadin reveals a role for Aurora B in correcting kinetochore-microtubule attachment and in maintaining the spindle assembly checkpoint, J Cell Biol, 161, 281, 10.1083/jcb.200208092 Lens, 2003, The survivin/Aurora B complex: its role in coordinating tension and attachment, Cell Cycle, 2, 507, 10.4161/cc.2.6.559 Carvalho, 2003, Survivin is required for stable checkpoint activation in Taxol-treated HeLa cells, J Cell Sci, 116, 2987, 10.1242/jcs.00612 Zhou, 2004, Survivin deregulation in β-tubulin mutant ovarian cancer cells underlies their compromised mitotic response to Taxol, Cancer Res, 64, 8708, 10.1158/0008-5472.CAN-04-2538 Fujie, 2005, Oxaliplatin, a potent inhibitor of survivin, enhances paclitaxel-induced apoptosis and mitotic catastrophe in colon cancer cells, Jpn J Clin Oncol, 35, 453, 10.1093/jjco/hyi130 Zaffaroni, 2002, Expression of the anti-apoptotic gene survivin correlates with Taxol resistance in human ovarian cancer, Cell Mol Life Sci, 59, 1406, 10.1007/s00018-002-8518-3 Zaffaroni, 2005, Survivin as a target for new anticancer interventions, J Cell Mol Med, 9, 360, 10.1111/j.1582-4934.2005.tb00361.x Eastman, 2004, Cell cycle checkpoints and their impact on anticancer therapeutic strategies, J Cell Biochem, 91, 223, 10.1002/jcb.10699 Woods, 1995, Taxol-induced mitotic block triggers rapid onset of a p53-independent apoptotic pathway, Mol Med, 1, 506, 10.1007/BF03401588 Weinstein, 1997, An information-intensive approach to the molecular pharmacology of cancer, Science, 275, 343, 10.1126/science.275.5298.343 Debernardis, 1997, p53 Status does not affect sensitivity of human ovarian cancer cell lines to paclitaxel, Cancer Res, 57, 870 Takahashi, 2000, Sensitivity to paclitaxel is not related to p53-dependent apoptosis in ovarian cancer cells, Eur J Cancer, 36, 1863, 10.1016/S0959-8049(00)00183-0 Osaki, 2000, Alteration of drug chemosensitivity caused by the adenovirus-mediated transfer of the wild-type p53 gene in human lung cancer cells, Cancer Gene Ther, 7, 300, 10.1038/sj.cgt.7700096 Sezgin, 2005, Potential predictive factors for response to weekly paclitaxel treatment in patients with metastatic breast cancer, J Chemother, 17, 96, 10.1179/joc.2005.17.1.96 Reinecke, 2005, Paclitaxel/Taxol sensitivity in human renal cell carcinoma is not determined by the p53 status, Cancer Lett, 222, 165, 10.1016/j.canlet.2004.09.045 Blagosklonny, 1995, Taxol induction of p21WAF1 and p53 requires c-raf-1, Cancer Res, 55, 4623 Giannakakou, 2001, Low concentrations of paclitaxel induce cell type-dependent p53, p21 and G1/G2 arrest instead of mitotic arrest: molecular determinants of paclitaxel-induced cytotoxicity, Oncogene, 20, 3806, 10.1038/sj.onc.1204487 Giannakakou, 2002, Enhanced microtubule-dependent trafficking and p53 nuclear accumulation by suppression of microtubule dynamics, Proc Natl Acad Sci USA, 99, 10855, 10.1073/pnas.132275599 Lanni, 1998, Characterization of the p53-dependent postmitotic checkpoint following spindle disruption, Mol Cell Biol, 18, 1055, 10.1128/MCB.18.2.1055 Di Leonardo, 1997, DNA replication in the presence of mitotic spindle inhibitors in human and mouse fibroblasts lacking either p53 or pRb function, Cancer Res, 57, 1013 Barboule, 1997, Involvement of p21 in mitotic exit after paclitaxel treatment in MCF-7 breast adenocarcinoma cell line, Oncogene, 15, 2867, 10.1038/sj.onc.1201469 Li, 1999, Overexpression of p21(waf1) decreases G2-M arrest and apoptosis induced by paclitaxel in human sarcoma cells lacking both p53 and functional Rb protein, Mol Pharmacol, 55, 1088, 10.1124/mol.55.6.1088 Baldwin, 1996, The NF-κB and IκB proteins: new discoveries and insights, Annu Rev Immunol, 14, 649, 10.1146/annurev.immunol.14.1.649 Dong, 2002, The function of multiple IκB: NF-κB complexes in the resistance of cancer cells to Taxol-induced apoptosis, Oncogene, 21, 6510, 10.1038/sj.onc.1205848 Huang, 2002, IκB kinase activation is involved in regulation of paclitaxel-induced apoptosis in human tumor cell lines, Mol Pharmacol, 61, 105, 10.1124/mol.61.1.105 Uzzo, 2002, Zinc inhibits nuclear factor-κB activation and sensitizes prostate cancer cells to cytotoxic agents, Clin Cancer Res, 8, 3579 Mabuchi, 2004, Inhibition of NF-κB increases the efficacy of cisplatin in vitro and in vivo ovarian cancer models, J Biol Chem, 279, 23477, 10.1074/jbc.M313709200 Patel, 2000, Paclitaxel sensitivity of breast cancer cells with constitutively active NF-κB is enhanced by IκBα super-repressor and parthenolide, Oncogene, 19, 4159, 10.1038/sj.onc.1203768 Pande, 2005, NF-κB in human disease: current inhibitors and prospects for de novo structure based design of inhibitors, Curr Med Chem, 12, 357, 10.2174/0929867053363180 Karin, 2004, The IKK NF-κB system: a treasure trove for drug development, Nat Rev Drug Discov, 3, 17, 10.1038/nrd1279 Mabuchi, 2004, Inhibition of inhibitor of nuclear factor-κB phosphorylation increases the efficacy of paclitaxel in vitro and in vivo ovarian cancer models, Clin Cancer Res, 10, 7645, 10.1158/1078-0432.CCR-04-0958 Fitzpatrick, 2003, The immunopharmacology of paclitaxel (Taxol), docetaxel (Taxotere), and related agents, Int Immunopharmacol, 3, 1699, 10.1016/j.intimp.2003.08.007 Huang, 2000, Nuclear factor-κB/IκB signaling pathway may contribute to the mediation of paclitaxel-induced apoptosis in solid tumor cells, Cancer Res, 60, 4426 LaCasse, 1998, The inhibitors of apoptosis (IAPs) and their emerging role in cancer, Oncogene, 17, 3247, 10.1038/sj.onc.1202569 Salvesen, 2002, IAP proteins: blocking the road to death’s door, Nat Rev Mol Cell Biol, 3, 401, 10.1038/nrm830 Mukaida, 2003, Pathophysiological roles of interleukin-8/CXCL8 in pulmonary diseases, Am J Physiol Lung Cell Mol Physiol, 284, L566, 10.1152/ajplung.00233.2002 Ishikawa, 2005, New biodefense strategies by neutrophils, Arch Immunol Ther Exp (Warsz), 53, 226 Collins, 2000, Paclitaxel up-regulates interleukin-8 synthesis in human lung carcinoma through an NF-κB- and AP-1-dependent mechanism, Cancer Immunol Immunother, 49, 78, 10.1007/s002620050605 Lee, 1996, Taxol-dependent transcriptional activation of IL-8 expression in a subset of human ovarian cancer, Cancer Res, 56, 1303 Duan, 1999, Discovery of differentially expressed genes associated with paclitaxel resistance using cDNA array technology: analysis of interleukin (IL) 6, IL-8, and monocyte chemotactic protein 1 in the paclitaxel-resistant phenotype, Clin Cancer Res, 5, 3445 Penson, 2000, Cytokines IL-1β, IL-2, IL-6, IL-8, MCP-1, GM-CSF and TNFα in patients with epithelial ovarian cancer and their relationship to treatment with paclitaxel, Int J Gynecol Cancer, 10, 33, 10.1046/j.1525-1438.2000.00003.x Mayerhofer, 2001, Interleukin-8 serum level shift in patients with ovarian carcinoma undergoing paclitaxel-containing chemotherapy, Cancer, 91, 388, 10.1002/1097-0142(20010115)91:2<388::AID-CNCR1013>3.0.CO;2-B Pusztai, 2004, Changes in plasma levels of inflammatory cytokines in response to paclitaxel chemotherapy, Cytokine, 25, 94, 10.1016/j.cyto.2003.10.004 Lee, 1997, Identification of tumor-specific paclitaxel (Taxol)-responsive regulatory elements in the interleukin-8 promoter, Mol Cell Biol, 17, 5097, 10.1128/MCB.17.9.5097 Lee, 2000, IL-8 reduced tumorigenicity of human ovarian cancer in vivo due to neutrophil infiltration, J Immunol, 164, 2769, 10.4049/jimmunol.164.5.2769 O’Brien, 1995, Taxol and colchicine increase LPS-induced pro-IL-1β production, but do not increase IL-1β secretion. A role for microtubules in the regulation of IL-1β production, J Immunol, 154, 4113, 10.4049/jimmunol.154.8.4113 White, 1998, Effects of paclitaxel on cytokine synthesis by unprimed human monocytes, T lymphocytes, and breast cancer cells, Cancer Immunol Immunother, 46, 104, 10.1007/s002620050468 Henkart, 1996, ICE family proteases: mediators of all apoptotic cell death?, Immunity, 4, 195, 10.1016/S1074-7613(00)80428-8 Cao, 2002, Many actions of cyclooxygenase-2 in cellular dynamics and in cancer, J Cell Physiol, 190, 279, 10.1002/jcp.10068 Ruegg, 2003, Non-steroidal anti-inflammatory drugs and COX-2 inhibitors as anti-cancer therapeutics: hypes, hopes and reality, Annu Med, 35, 476, 10.1080/07853890310017053 Moos, 1998, Taxane-mediated gene induction is independent of microtubule stabilization: induction of transcription regulators and enzymes that modulate inflammation and apoptosis, Proc Natl Acad Sci USA, 95, 3896, 10.1073/pnas.95.7.3896 Subbaramaiah, 2000, Microtubule-interfering agents stimulate the transcription of cyclooxygenase-2. Evidence for involvement of ERK1/2 AND p38 mitogen-activated protein kinase pathways, J Biol Chem, 275, 14838, 10.1074/jbc.275.20.14838 Subbaramaiah, 2003, Regulation of cyclooxgenase-2 mRNA stability by taxanes: evidence for involvement of p38, MAPKAPK-2, and HuR, J Biol Chem, 278, 37637, 10.1074/jbc.M301481200 Altorki, 2005, Chemotherapy induces the expression of cyclooxygenase-2 in non-small cell lung cancer, Clin Cancer Res, 11, 4191, 10.1158/1078-0432.CCR-05-0108 Choy, 2003, Enhancing radiotherapy with cyclooxygenase-2 enzyme inhibitors: a rational advance?, J Natl Cancer Inst, 95, 1440, 10.1093/jnci/djg058 Hida, 2002, Significant growth inhibition of human lung cancer cells both in vitro and in vivo by the combined use of a selective cyclooxygenase-2 inhibitor, JTE-522, and conventional anticancer agents, Clin Cancer Res, 8, 2443 Dandekar, 2005, Cyclooxygenase-2 inhibitor celecoxib augments chemotherapeutic drug-induced apoptosis by enhancing activation of caspase-3 and -9 in prostate cancer cells, Int J Cancer, 115, 484, 10.1002/ijc.20878 Shaik, 2006, Enhancement of antitumor activity of docetaxel by celecoxib in lung tumors, Int J Cancer, 118, 396, 10.1002/ijc.21325 Nugent, 2005, Docetaxel and cyclooxygenase-2 inhibition with celecoxib for advanced non-small cell lung cancer progressing after platinum-based chemotherapy: a multicenter phase II trial, Lung Cancer, 48, 267, 10.1016/j.lungcan.2004.11.004 Gasparini, 2005, The combination of the selective cyclooxygenase-2 inhibitor celecoxib with weekly paclitaxel is a safe and active second-line therapy for non-small cell lung cancer: a phase II study with biological correlates, Cancer J, 11, 209, 10.1097/00130404-200505000-00007 Altorki, 2003, Celecoxib, a selective cyclooxygenase-2 inhibitor, enhances the response to preoperative paclitaxel and carboplatin in early-stage non-small-cell lung cancer, J Clin Oncol, 21, 2645, 10.1200/JCO.2003.07.127 Datta, 1999, Cellular survival: a play in three Akts, Genes Dev, 13, 2905, 10.1101/gad.13.22.2905 Plas, 2005, Akt-dependent transformation: there is more to growth than just surviving, Oncogene, 24, 7435, 10.1038/sj.onc.1209097 Zimmermann, 1999, Phosphorylation and regulation of Raf by Akt (protein kinase B), Science, 286, 1741, 10.1126/science.286.5445.1741 Cheng, 2005, The Akt/PKB pathway: molecular target for cancer drug discovery, Oncogene, 24, 7482, 10.1038/sj.onc.1209088 Mitsuuchi, 2000, The phosphatidylinositol 3-kinase/AKT signal transduction pathway plays a critical role in the expression of p21WAF1/CIP1/SDI1 induced by cisplatin and paclitaxel, Cancer Res, 60, 5390 MacKeigan, 2002, Inactivation of the antiapoptotic phosphatidylinositol 3-kinase-Akt pathway by the combined treatment of Taxol and mitogen-activated protein kinase inhibition, Clin Cancer Res, 8, 2091 Hu, 2002, Inhibition of phosphatidylinositol 3′-kinase increases efficacy of paclitaxel in vitro and in vivo ovarian cancer models, Cancer Res, 62, 1087 Lin, 2003, Reversal of Taxol resistance in hepatoma by cyclosporin A: involvement of the PI-3 kinase-AKT 1 pathway, Br J Cancer, 88, 973, 10.1038/sj.bjc.6600788 Shingu, 2003, Synergistic augmentation of antimicrotubule agent-induced cytotoxicity by a phosphoinositide 3-kinase inhibitor in human malignant glioma cells, Cancer Res, 63, 4044 Asnaghi, 2004, mTOR: a protein kinase switching between life and death, Pharmacol Res, 50, 545, 10.1016/j.phrs.2004.03.007 Le, 2003, Paclitaxel induces inactivation of p70 S6 kinase and phosphorylation of Thr421 and Ser424 via multiple signaling pathways in mitosis, Oncogene, 22, 484, 10.1038/sj.onc.1206175 Koff, 1995, p27KIP1, an inhibitor of cyclin-dependent kinases, Prog Cell Cycle Res, 1, 141, 10.1007/978-1-4615-1809-9_11 Dumont, 1996, Mechanism of action of the immunosuppressant rapamycin, Life Sci, 58, 373, 10.1016/0024-3205(95)02233-3 Calastretti, 2001, Damaged microtubules can inactivate BCL-2 by means of the mTOR kinase, Oncogene, 20, 6172, 10.1038/sj.onc.1204751 VanderWeele, 2004, Akt up-regulation increases resistance to microtubule-directed chemotherapeutic agents through mammalian target of rapamycin, Mol Cancer Ther, 3, 1605, 10.1158/1535-7163.1605.3.12